Slide 1: Pioneering Gene Therapies for Large Patient Populations
7 Genprex’ PIONEERING GENE THERAPIES FOR LARGE PATIENT POPULATIONS NASDAQ: GNPX November 2022
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Reform Act of oF at all plan to initiate, achievement of key milestones, our Pl 6 of other the clinical i he timing ofour P ever be Issued u i ‘These anc other under the capt our: 2021 and our other flings business or materially require by compary, 1 maria wth al rights an
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM. FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS LARGE MARKETS AND UNMET NEED TWO FDA FAST TRACK DESIGNATIONS SHOWN CLINICAL ACHIEVEMENT \ d + TWO LUNG CANCER CLINICAL TRIALS CURRENTLY ENROLLING + NOVEL GENE THERAPY PROGR
Slide 4: Advancing Gene Therapy in Large Indications
ADVANCING GENE THERAPY IN LARGE INDICATIONS HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES. ‘* REQORSA® is the first systemic gene therapy in development for cancer. ‘© Initially targeting solid tumors in lung cancers. ‘* Clinical trials include combinations of REQORSA with AstraZ
Slide 5: Research and Development Pipeline
© Genprex RESEARCH AND DEVELOPMENT PIPELINE oncotoey a FEQORSAYIMMUNOGENE THERAPY nscuc onccons" feqorsismennocereTienary _wscie_—«=«Aclav-1_ ESS ee a REQORSA* INMUNOGENE THERAPY nscic Acctaim:2 SESS a REQORSA*IMMUNOGENE THERAPY seu onc sco unossxoseo = Dianeres wee a CY a Nasdaq GNPX. 5
Slide 6: Oncology Program
ONCOLOGY PROGRAM REPROGRAMMING THE COURSE OF CANCER:
Slide 7: Lead Program: Non-Small Cell Lung Cancer
LEAD PROGRAM: NON-SMALL CELL LUNG CANCER RECENT EXPANSION TO SCLC COVERS VIRTUALLY ENTIRE MARKET 49 MOST COMMON LUNG CANCER TAGRISSO 2021 SALES NSCLC represents the majority ofall lung cancers’. AstraZeneca's highest grossing product. WORLDWIDE LUNG CANCER CASES KEYTRUDA 2021 SALES More than two mil
Slide 8: Tumor Suppressor Genes Deleted During Cancer Development
TUMOR SUPPRESSOR GENES DELETED DURING CANCER DEVELOPMENT ‘Tumor suppressor genes such as TUSC2 are deleted early during cancer development 80% of all non-small cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein Loss or reduction of TUSC2 expression is associated with signi
Slide 9: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES SYNERGIES Multiple tumor ‘Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers. Genprex Nasdaq oNPX
Slide 10: Oncoprex Nanoparticle Delivery System
ONCOPREX® NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS gene REQORSA® IMMUNOGENE THERAPY Next gen non-viral, positively-charged lipid ‘cle (LNP) i ically delivered ©) Genprex Nasdag:GNeX 10
Slide 11: Selective Uptake of REQORSA
SELECTIVE UPTAKE OF REQORSA® PATIENT 2 (0.06 mg/kg) PATIENT 1 (0.02 mg/kg) PRE-TREATMENT BIOPSIES POST-TREATMENT BIOPSIES etal Post 2012, In all images, blue stain shows cell nuclei and red stain shows TUSC2 protein Nasdag:GNex 11
Slide 12: REQORSA Targets Cancer at Its Core
REQORSA TARGETS CANCER AT ITS CORE MULTIPLE ANTI-CANCER MECHANISMS OF ACTION CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Genprex ossagsonex
Slide 13: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients, Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Highest dose used
Slide 14: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS. e PRIOR LINES OF PATIENT EGFR STATUS RESPONSE PRIOR THERAPY | THERAPY Positive (exon 18*20) Complete Response Chemo 3 Negative 240% regression Target Lesion Chemo /anti-PD1 2 30% regression one Target Lesion : Neg
Slide 15: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS " asm ;_ n settee ee t +—}—+ + ‘Osimertinib+TUSC2 combination on ‘Osimertinib+TUSC2 combination on H1975-OsiR tumors in NSG mice Hp eyehlnpcte wll ; - be E H i es g tn be an | e rt 00001 v9 Om 10 e at 025 O29 052 036 O39 Dw
Slide 16: Acclaim-1 General Study Characteristics
PHASE 1 GENERAL STUDY CHARACTERISTICS FDA Fast Track Designation Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso ~ sites + ~158 patients Phase 1 Dose Escalation: ~ Phase 1 Dose Expansion: ~66 patients Phase 2: ~74 patients Interim analysis at 25 events (i.e,, diseas
Slide 17: Acclaim-1 Study Design
Acelayn PHASE 1 Bey stupy Desicn PRIMARY ENDPOINT GE. 3+3 dose escalation of + Dose limiting toxicity = REQORSA in combination a with Tagrisso = PHASE 2 B STUDY DESIGN FRIMARY ENDPOINT, SECONDARY ENDPOINTS fi .- Randomized 1:1, open- + Progression free survival (PFS) + Overall response rate Zz label
Slide 18: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model z usc? = yusca-POt a [USC2+POISCTLAS zo é bays TUSC2+anti-PD1 exhibit greater antitumor activity than boca D a aus ncomen atonement prolonged su
Slide 19: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda The independent immunologic effects of REQORSA and Keytruda create synergy by adding increased immunologic attack on the tumor to PD+1 inhibition, Genprex —pentroteum
Slide 20: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA + Keytruda + Chemo KL-mutant lung metastases in humanized mice. + REQORSA enhances the efficacy of + Triple combination demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL}-mutant NSCLC in clin
Slide 21: Acclaim-2 General Study Characteristics
GENERAL STUDY CHARACTERISTICS. ete : ° «FDA Fast Track Designation (received December 2021) 1 | | ire + Patients dv ft Pele treatment with Keytruda + -10US. sites cc aim e + ~156 patients phase po apa REQORSA.n combination wih Merck Co's Keytruda for NSCLC Interim analysis at 50 events (Le, disease
Slide 22: Acclaim-2 Study Design
Acclaim -2 STUDY DESIGN PRIMARY ENDPOINT + 343 dose escalation of + Dose limiting toxicity REQORSA in combination with Keytruda PHASE 1 COMPONENT iS STUDY DESIGN PRIMARY ENDPOINT SECONDARY ENDPOINTS ag + Randomized 2:1, open- «Progression free survival (PFS) + Overall response rate é 8 wz label, 2-a
Slide 23: REQORSA in Small Cell Lung Cancer
REQORSA IN SMALL CELL LUNG CANCER Targeting Small Cell Lung Cancer (in addition to NSCLO) allows Genprex to address virtually the entire lung cancer market. ‘Small Cell Lung Cancer: + Consistently has low TUSC2 protein levels, Documented to often have deletion of one TUSC2 gene allele Extensive stag
Slide 24: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET FOCUS ON . _ . GROWTH Achievement highlighted by important process i and signi improved of scale. Successful completion of technology transfer and scale-up of REQORSA + GMP production process will
Slide 25: Diabetes Program
DIABETES PROGRAM
Slide 26: Diabetes Program
DIABETES PROGRAM COLLABORATION WITH UNIVERSITY OF PITTSBURGH TO TREAT DIABETES. 37.3M or 11.3% of Americans Have Diabetes' Type 1 Diabetes: An auto-immune condition where the body's immune system destroys pancreatic beta cells that make insulin. Generally occurs in children and adolescents. Type 2 D
Slide 27: Diabetes: A Global Epidemic
DIABETES: A GLOBAL EPIDEMIC 537M DIABETES PREVELANCE - GLOBAL? Expected to rise to 643M by 2030 and 783M by 2045. 37.3M DIABETES PREVELANCE - USA? 96M US. adults (38% population) have prediabetes, 6.7M ANNUAL MORTALITY GLO! BAL Approximately 1 death every 5 seconds in 2021, Sikdenths nthe US cased b
Slide 28: Diabetes Causes Serious Complications
DIABETES CAUSES SERIOUS COMPLICATIONS HEART DISEASE Leading cause of death for men and women in US. Diabetics are 2x as likely to have heart disease or a stroke. CHRONIC KIDNEY DISEASE (CKD) Approximately 1 in 3 adults with diabetes have CKD. Kidney diseases are the 9" leading cause of death in U.S.
Slide 29: Diabetic Patients in Need of Advanced Therapy
DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY GPX-002 HOLDS POTENTIAL TO ADDRESS DISEASE AT ITS CORE FOR LONG-TERM EFFECTIVENESS epssemmlalpangess gaa Insuln tat Despite certain advancements in treatment, quality of life remains highly compromised | for many with diabetes. GPX.002 holds potential to
Slide 30: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdx1 + MafA (PM) genes to neces e Euacemia the pancreas. InT10, it transforms alpha cells in the pancreas into functional beta-ike cells, which can pr
Slide 31: GPX-002 Reversed Drug-Induced Diabetes in Mice
Blood glucose (mola) GPX-002 REVERSED DRUG-INDUCED DIABETES IN MICE alloxan AAV-8 injection ~ Green Fluorescent Protein fluorescent marker) PM = Pax + Mok Diabetes, Cell Stem Celt 2018;2211,78 90.04 dor t0. 1016), stem.2017.11.020. beta cell mass (mg) ino X, Guo P, Shiota Cea. Endogenous Reprogrammi
Slide 32: GPX-002 Restored Blood Glucose in T1D Mouse Model
GPX-002 RESTORED BLOOD GLUCOSE IN T1D MOUSE MODEL ‘Blood gucose (mois) FOR FOUR MONTHS GFP= Green Fluorescent Protein ituoreseent marker) PM = Pal + Mat Beta cell mass (mg) eS Nol NoD AAV-GFPAAV-PM a a eS “Tine ees) + One week in a mouse tends to correlate to about one year in humans. + The average
Slide 33: GPX-002 Induces Generation of Functional Insulin
GPX-002 INDUCES GENERATION OF FUNCTIONAL INSULIN EXPRESSING CELLS FROM ALPHA CELLS IN HUMAN ISLETS ° G10 S Fiorescert Protein s = *e {tuerescent mare g 8 PM = Bet «Mat 8 i E 4 8 05 H g 3 8 = & co) o| STZ/AAV-GFP_ STZ/AAV-PM. ALX islettransplantation Analysis Human islets treated with streptozotocin
Slide 34: GPX-002 Reduces Insulin Requirements in Non-Human Primate Model
GPX-002 REDUCES INSULIN REQUIREMENTS IN NON-HUMAN PRIMATE MODEL OF T1D il Lai hu i | Hla }
Slide 35: Rejuvenates and Replenishes Beta Cells in T2D
REJUVENATES AND REPLENISHES BETA CELLS IN T2D + 72D stresses beta cells and their insulin production. + GPX.002 appears to replenish and rejuvenate beta cells and insulin production. + Sponsored Research Agreement supports ‘ongoing non-human primate studies in T2D. Opportunity to lead disease modify
Slide 36: Corporate
Slide 37: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT Ai RODNEY VARNER, JD CATHERINE VACZY, JD Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer + saeyearsof experi in crparate lan lng Corporate governance in biotech industry + 20+ years of experience in senior executiv
Slide 38: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ years of expertise in biotech Paw, business evelopment, licensing tra w Seana! Weunteant alone DAVID SCHLOSS, JD Senior Vice President, Human Resources + 25+ years of experience as
Slide 39: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD pete EASTERD JANNE JACK A. ROTH MD, FACS, Chairman Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracic and Cardiovascular Surgery; Chief, Section of Thoracic Molecular Oncology; Professor of Molecular and Cellular ‘Oncology: UT MD An
Slide 40: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD. MICHAEL MORSE a hae eese PEOPLES MD, MHS, FACP . + Professor of Medicine, Division of Medical Oncology © aerpcens omer cone: nggntice inthe Depactment of Surgery at Duke Unversity . bau cancer mmuntiran CRO + Research expertise in targeted therapies and + Profe
Slide 41: Board of Directors
MEET OUR TEAM RODNEY VARNER, JD Chairman of the Board 30+ years of expertise in corporate law, including ‘corporate governance, in biotech industry + Former owner of securities broker dealer frm JOSE A. MORENO TOSCANO, Board Director Chief Executive Officer, LFB USA Inc 20+ years of experience in ph
Slide 42: GNPX at a Glance
GNPX AT A GLANCE company | SYMBOL Marker cap | 30:DAYAVG OUTSTANDING Genprex, Inc. GNPX Nasdaq. $1.28 $61.5M 94K 48,020,324 $25.5 Million © Genprex Nasdaq: GNPX 42,
Slide 43: Achievements and Upcoming Milestones
ACHIEVEMENTS AND UPCOMING MILESTONES RECENT ACHIEVEMENTS Y Dose the first patient in Acclaim-2 Vv Approval from Safety Review Committee to advance Acclaim-1 to higher dosing in second cohort of Phase 1 portion of study Y Expand indications to small cell lung cancer (expand on sponsored research) Vv
Slide 44: In a Future of Transformational Patient Care
IN A FUTURE OF TRANSFORMATIONAL PATIENT CARE 21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS EXPLORING NEW INDICATIONS AND PARTNERSHIPS
Slide 45: Genprex Contact
a) Genprex’ NASDAQ: GNPX (877) 74-GNPX | investors@genprex.com Nasdaq GNPX.